Successful treatment of essential thrombocythemia with anagrelide in a child

Hermann, J; Fuchs, D.; Sauerbrey, Axel; Hempel, Lutz; Zintl, F

doi:10.1002/(sici)1096-911x(199806)30:6<367::aid-mpo13>3.0.co;2-f

Cited by 9 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two had severe venous thrombosis, involving the mesenteric, hepatic and portal veins and a cerebral venous sinus (Mitus et al , 1990; Lackner et al , 1998). An additional two had recurrent severe headaches, parasthesias of the extremities, and erythromelalgia (Hermann et al , 1998; Chintagumpala et al , 1991). No patient had combined bleeding and thrombotic events.…”

Section: Clinical Featuresmentioning

confidence: 99%

“…This review summarizes the clinical and laboratory characteristics and management of ET in children, based on a review of 40 paediatric cases reported in the English literature up to September 1998 (Amato & Freedman, 1984; Barnhart et al , 1980; Chintagumpala et al , 1991; Cohen et al , 1997; Eyster et al , 1986; Fernandez‐Robles et al , 1990; Fickers & Speck, 1974; Freedman et al , 1973; Hermann et al , 1998; Hoagland & Silverstein, 1978; Host & Saunamaki, 1992; Kapoor et al , 1996; Kikawa et al , 1998; Kikuchi et al , 1995; Lackner et al , 1998; Lahuerta‐Palacios et al , 1988; Linch et al , 1982; Lumley, 1971; Mitus et al , 1990; Ozer et al , 1960; Sceats & Baitlon, 1980; Schlemper et al , 1994; Slee et al , 1981; Spach et al , 1963; van Dijken et al , 1996; Williams & Shahidi, 1991; Yoshida et al , 1998), and on experience with the disease at our institution (two patients; Dror et al , 1999). The review discusses the similarities and differences of the disease in adults and children, and its familial occurrence.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Essential thrombocythaemia in children

Dror

Blanchette

1999

Br J Haematol

View full text Add to dashboard Cite

Section: Clinical Featuresmentioning

confidence: 99%

mentioning

confidence: 99%

Essential thrombocythaemia in children

Dror

Blanchette

1999

Br J Haematol

View full text Add to dashboard Cite

“…Its use should also limit the discomfort of chronic subcutaneous administration. So far, two children have been treated with IFN [8,29].…”

Section: Newer Platelet-lowering Drugs 321 Interferon-αmentioning

confidence: 99%

“…No leukaemic evolution has actually been reported in anagrelide-treated ET patients. Two paediatric cases have been reported that suggest anagrelide may also be beneficial in children [29,32].…”

Section: Anagrelidementioning

confidence: 99%

“…Furthermore, concern exists about the leukaemogenic potential of drugs for lowering platelet number; however, it is noteworthy that none of the paediatric patients treated with hydroxyurea underwent malignant transformation. Anagrelide controls extreme thrombocytosis and the only two available cases [29,32] treated with such a drug suggest no carcinogenetic effects.…”

Section: Treatment Experience In Children With Essential Thrombocythamentioning

confidence: 99%

See 1 more Smart Citation

Essential thrombocythaemia in children: is a treatment needed?

Randi¹,

Putti²

2004

eoph

View full text Add to dashboard Cite

The myeloproliferative disorder, essential thrombocythaemia (ET), is extremely rare in children. In adults, thrombosis is the most common complication whereas a low number of children develop thrombosis and/or haemorrhages. Diagnosis of ET is often difficult, but identifying ET from other causes of thrombocytosis is essential, otherwise therapy may be ineffective as the wrong disease will be treated. Only anecdotal experiences have been published with regard to the treatment of paediatric ET. A watch-and-wait strategy seems appropriate in asymptomatic cases and low-dose aspirin should be used to reduce microvascular disturbances. Anagrelide or IFNs may be considered as first-line, and hydroxyurea as second-line therapy. Anagrelide may become the treatment of choice for ET in children if a lack of leukaemogenic potential is confirmed.

show abstract

Essential thrombocythemia in a child with elevated thrombopoietin concentrations and skeletal anomalies

Robins

Niazi

2007

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Essential thrombocythemia is a rare myleoproliferative disorder in pediatrics. This myleoproliferative disorder is characterized by excessive proliferation of megakaryocytes and sustained elevation of platelet count. Reactive thrombocytosis is a more common cause of elevated platelet counts among children. We describe a 2-year-old child with essential thrombocythemia, skeletal anomalies, and elevated thrombopoietin concentrations. The child's mother was also subsequently diagnosed with essential thrombocythemia and had elevated thrombopoietin concentrations. Chromosomal studies on the mother, child and other family members were normal.

show abstract

Successful treatment of essential thrombocythemia with anagrelide in a child

Cited by 9 publications

References 12 publications

Essential thrombocythaemia in children

Essential thrombocythaemia in children

Essential thrombocythaemia in children: is a treatment needed?

Essential thrombocythemia in a child with elevated thrombopoietin concentrations and skeletal anomalies

Contact Info

Product

Resources

About